Zelluna ASA
The answer first
Does Zelluna beat the market?
Yes, Zelluna has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 40% of Nordic stocks
- Quality99
- Value2
- Trend40
No. 79 of 195 in healthcare
Max for seven days
Follow Zelluna with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Zelluna
Your first answer is free, no account needed.
Do you own Zelluna, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Zelluna and a few more. Free, no card.
Super Stock+46.4%In short
- Zelluna has risen 75.6% over the past year, including dividends.
- Overall, Zelluna ranks better than 40% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 99.5%. The price is 99.0% below its peak now.
Who owns Zelluna? See the major shareholders and their stakes
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 40% of Nordic stocks.
No. 79 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 3 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.01
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−128.5%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 183 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity5.3
- P/SPrice divided by sales–
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 90 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−26.8%
- 6 months−29.1%
- 9 months−2.8%
- 12 months+75.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Zelluna
Zelluna ASA is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 15 employees.
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.


See the full analysis of Zelluna.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card